



For Immediate Release:

Intranasal Technology, Inc. and Aegis Therapeutics expand on their collaborative agreement and will pursue intranasal heparin and β -interferon using Aegis' Intravail™ Drug Delivery Technology

LEXINGTON, KY & SAN DIEGO, CA--(BUSINESS WIRE)--June 20, 2005--Intranasal Technology, Inc. ("ITI") and Aegis Therapeutics ("Aegis") today announced that they have expanded their collaborative agreement to apply Aegis' patented Intravail™ drug delivery technology to intranasal heparin and β -interferon.

"The Intravail(TM) drug delivery technology for protein and peptide therapeutics fits nicely into our strategy of developing unparalleled product offerings in the nasal drug delivery arena," said John C. Carlisle, ITI President and Chief Executive Officer. "Intravail's remarkable bioavailability and safety data, along with ITI's fully integrated product development and manufacturing capabilities, will allow us to accelerate our efforts to bring a product to market quickly that improves safety, efficacy and convenience for patients, their caregivers and physicians."

ITI is working on the development of a number of new drug formulations and technologies for nasal delivery, including sedatives, anticonvulsants, and medications for migraine headache and panic disorder. The addition of heparin and β -interferon will address the need for an easily administered antithrombotic medication as well as extend central nervous system applications. ITI has performed 18 human trials, and a patent has been issued for the lorazepam nasal spray formulation and related delivery technology. Patents will be filed on all ITI-developed compounds.

"ITI has an impressive product pipeline and unique manufacturing process currently focused on the nasal administration of small molecule therapeutics," said Edward T. Maggio, Ph.D., Aegis' President and Chief Executive Officer. "The application of Aegis' non-invasive drug delivery technology to a new intranasal heparin and β -interferon provides ITI a unique benefit as it develops exciting new therapeutic products that hold advantages for both patients and healthcare professionals."

Aegis' Intravail(TM) absorption enhancement agents are mild and non-irritating to mucosal membranes, providing exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection. Via the intranasal, ocular and other mucosal membrane administration routes, these agents help deliver potent peptide, protein, and large molecule drugs that currently can be delivered only by injection.

Nasal drug delivery has numerous benefits for patients and healthcare professionals, including rapid onset of action, non-invasive and virtually pain-free delivery, and the elimination of needles and biohazardous wastes. In addition, nasally delivered drugs have the potential for direct transfer across the blood brain barrier, which could improve the efficacy of many central nervous system products.

CONTACT INFORMATION:

For Aegis Therapeutics:

Edward T. Maggio, Ph.D.
President and CEO
Aegis Therapeutics LLC
16870 W. Bernardo Drive,
Suite 390
San Diego, CA 92127
Tel: 858.618.1400 Ext. 101
FAX: 858.618.1441
Email: emaggio@aegisthera.com

For ITI:

John C. Carlisle
President and CEO
Coldstream Research Campus
1513 Bull Lea Boulevard
Lexington, KY 40511-1200
Phone: 859-252-5050
Fax: 859-252-7280
Email: jcarlisle@intranasal.com



About Aegis Therapeutics

Aegis Therapeutics is a specialty pharmaceutical company formed to commercialize advanced patented drug delivery technologies that enable the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics. Aegis' Intravail™ absorption agents have numerous competitive advantages, including rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier with no or minimal irritation, avoidance of gastric hydrolysis in the stomach and “first pass effect” elimination by the liver that can accompany oral administration, greater patient convenience and compliance, elimination of needlestick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, ease of formulation and compatibility with routine homogeneous formulation and dispensing manufacturing processes for ease of scale-up and production. For more information about Aegis, please visit www.aegisthera.com.

About ITI

Intranasal Technology, Inc. (ITI) is a specialty pharmaceutical company that develops rapid onset prescription drug formulations and innovative nasal drug delivery products to address unmet clinical needs. ITI develops new and differentiated proprietary products by expertly combining its formulation research expertise, clinical evaluation capability, delivery systems technology, and the aseptic manufacturing and packaging of nasal spray drug products. The Company controls all key aspects of the development cycle to ensure that products get to market quickly and efficiently. ITI currently is focused on nasally delivered analgesics and anxiolytics, and is seeking partners to market existing compounds and newly acquired compounds that offer significant clinical benefits and market potential. For more information please visit <http://www.intranasal.com>.

CONTACT INFORMATION:

For Aegis Therapeutics:

Edward T.Maggio, Ph.D
President and CEO
Aegis Therapeutics LLC
16870 W. Bernardo Drive,
Suite 390
San Diego, CA 92127
Tel: 858.618.1400 Ext. 101
FAX: 858.618.1441
Email: emaggio@aegisthera.com

For ITI:

John C. Carlisle
President and CEO
Coldstream Research Campus
1513 Bull Lea Boulevard
Lexington, KY 40511-1200
Phone: 859-252-5050
Fax: 859-252-7280
Email: jcarlisle@intranasal.com